Overview

Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide

Phase:

Phase 1

Details

Lead Sponsor:

Innate Pharma

Treatments:

Antibodies, Monoclonal
Lenalidomide
Thalidomide